Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.489702
Title: Aberrant translational control in non-Hodgkin's lymphoma
Author: Goodrem, Peter
ISNI:       0000 0001 3505 1084
Awarding Body: University of Nottingham
Current Institution: University of Nottingham
Date of Award: 2007
Availability of Full Text:
Access from EThOS:
Abstract:
Non-Hodgkin's Lymphoma (NHL) is a group ofhaematological malignancies that encompasses thirty individual disease subtypes. The most common subtypes are the Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Together, there are 8,500 new NHL cases diagnosed annually in the UK, with FL and DLBCL making up between 55-60% of these cases. Both are treatable, but are ultimately incurable, with treated indolent FL often relapsing as the more aggressive DLBCL. Much is know about their disease biology, however analysis of their. translation status is yet to be examined. By coupling polysome gradients with cDNA microarray, a translation profile was constructed of a panel of control and NHL cell lines that showed the translation status of over 5,200 different mRNAs clones. The data indicated that approximately 10% of the clones were more translationalIy active in the NHL celIs, and approximately 45% were translationalIy repressed. MRNAs in the translationally active subset included those coding for survival, signalling, transcription factors and anti-apoptosis protein, while those that were translationally repressed included proapoptotic proteins, apoptotic machinery, ceIl-cycle control proteins, and proteins involved with protein degradation and turnover. The large data set produced correlated welI with the biology already known about these cells, and primary FLIDLBCL, and it also included a number of genes that could be targeted as new potential avenues for therapy. The data was successfulIy used to predict the behaviour of the celIs treated with apoptotic stimuli, and used to determine whether cells would be sensitive, or could be sensitised to different therapies.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.489702  DOI: Not available
Share: